ILMN
ILLUMINA, INC.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$262.66
+0.05%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$268.93
From 52W high−10.57%
Volume1.90M
Market cap$39.66B
P/E (TTM)48.6x
P/S (TTM)8.8x
Div yield—
Key dataOct 19, 2026
Open
$268.93
From 52W high
−10.57%
Volume
1.90M
Market cap
$39.66B
ValuationView details →
P/E (Fwd)
44.4x
EV/EBITDA
30.1x
P/E (TTM)
48.6x
RSI (14)
53.5
MomentumView details →
1D Return
+0.05%
YTD Return
+100.65%
SummaryUpdated Jun 1, 2026
Illumina, Inc. (NASDAQ:ILMN) is a leading biotechnology company founded in 1998 and based in San Diego, California, that went public in 2000. The company pioneered the development of DNA sequencing and array-based solutions that have revolutionized genetic and genomic analysis. Over its 25+ year history, Illumina has established itself as the dominant player in the DNA sequencing market, providing the foundational technology that enables genomic research, clinical diagnostics, and personalized medicine applications worldwide.
Similar companies
Latest newsMore news →
ILLUMINA, INC. launched BioInsight, its first unified software environment, designed to accelerate advances in genomics and multiomics.5d agoIllumina established an unsecured commercial paper program with up to $1.0 billion of notes outstanding, with proceeds intended for general corporate purposes.6d agoILLUMINA, INC. launched SpliceAI2 for rare disease research.11d ago